Systematic Reviews
Copyright ©The Author(s) 2022.
World J Transplant. Jun 18, 2022; 12(6): 131-141
Published online Jun 18, 2022. doi: 10.5500/wjt.v12.i6.131
Table 1 Clinical-pathological features of the study populations
Clinical features
Oligodendroglioma (%)
Astrocytoma (%)
Patients90 (100)67 (100)
Sex
Male52 (58)39 (58)
Female32 (35)27 (40)
Undisclosed6 (7)1 (2)
Age in yr1.5-74.0 (mean: 44.5; median: 46)0-82.0 (mean: 31.0, median: 26)
Location
Frontal lobe34 (38)7 (11)
Parietal lobe8 (9)2 (3)
Temporal lobe5 (6)11 (16)
Spine1 (1)6 (9)
NA22 (24)2 (3)
Other sites20 (22)39 (58)
Surgery
Yes79 (88)48 (71)
No2 (2)16 (24)
Multiple surgeries
Yes44 (49)24 (36)
No35 (39)41 (61)
Radiotherapy
Yes60 (67)49 (73)
No14 (15)15 (22)
Chemotherapy
Yes33 (37)16 (23)
No37 (41)48 (72)
VA/VP shunt
Yes3 (3)20 (30)
No26 (29)34 (50)
Metastatic sites
Bone48 (53)30 (44)
Bone marrow30 (33)6 (8)
Lymph nodes27 (30)24 (30)
Cervical 16 (17)14 (17)
Retroperitoneal 3 (3)2 (3)
Axillary2 (2)-
Other6 (7)7 (10)
Lung10 (11)11 (17)
Liver8 (9)8 (11)
Scalp8 (9)8 (11)
Pleura5 (6)6 (8)
Parotid gland5 (6)3 (4)
Breast3 (3)-
Chest wall3 (3)1 (1)
Peritoneum3 (3)10 (14)
Kidney-3 (4)
Retroperitoneum2 (2)1 (1)
Soft tissues1 (1)11 (15)
Pericardium1 (1)-
Pancreas1 (1)1 (1)
Spleen1 (1)-
Thymus/mediastinum1 (1)1 (1)
Adrenal gland1 (1)-
Muscles3 (3)2 (3)
Intra-CNS metastases/recurrence
Yes43 (48)37 (55)
No19 (21)26 (39)
Non-conclusive1 (1)3 (6)
Time from the diagnosis to metastatic spread0-324 (mean: 53.7; median: 36)0-276 (mean: 31.0; median: 13)